EGFR and non-small cell lung carcinoma: Another just released report did confirm that osimertinib, like the EGFR-TKIs of 1G and 2G [246,247,248,249], increases the autophagic activity of EGFRM+ NSCLC cells in vitro and in xenograft mice, however, it concluded that this resulted in the development of osimertinib-resistant cells exhibiting stem cell-like properties [251].